JPS58201981A - Cultivation of cell of microorganism - Google Patents

Cultivation of cell of microorganism

Info

Publication number
JPS58201981A
JPS58201981A JP57084623A JP8462382A JPS58201981A JP S58201981 A JPS58201981 A JP S58201981A JP 57084623 A JP57084623 A JP 57084623A JP 8462382 A JP8462382 A JP 8462382A JP S58201981 A JPS58201981 A JP S58201981A
Authority
JP
Japan
Prior art keywords
virus
cell
viruses
culture
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP57084623A
Other languages
Japanese (ja)
Inventor
Yasuhiko Ozaki
安彦 尾崎
Masao Kageyama
影山 雅夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unitika Ltd
Original Assignee
Unitika Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unitika Ltd filed Critical Unitika Ltd
Priority to JP57084623A priority Critical patent/JPS58201981A/en
Publication of JPS58201981A publication Critical patent/JPS58201981A/en
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE:To prevent the bacteriolysis of host caused by viruses, and to cultivate a cell or microorganism smoothly without inhibition, by adding serum containing an antibody to neutralize the viruses to a medium, cultivating the cell or microorganism. CONSTITUTION:In cultivating a cell or microorganism, serum containing an antibody to neutralize viruses is added to a medium. A cell derived from mammals or various kinds of hybridomas prepared by cell fusion may be cited as the cell. Ray fungs, bacteria, etc. may be cited as the microorganism. A rabbit is suitable as the animal because of easy acquisition and a large amount of blood, and a guinea pig, rat, dog, sheep, etc. may be used. As to period to add the serum containing an antibody to neutralyze the viruses to the cell or microorganism, any period during cultivation may be available, and the addition at the beginning of cultivation is especially preferable.

Description

【発明の詳細な説明】 本発明は、i胞又は微生物の培養方法に関するものであ
り、さらに詳しくは、細胞又は微生物を培養するに際し
て発生するウィルス汚染を防」卜するKあたり、培地中
にウィルスに特異的な抗血清を添加することにより、ウ
ィルスによる宿主の溶菌を防止し、その培養を阻害なく
m調に行わしめる方法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for culturing cells or microorganisms, and more specifically, to prevent virus contamination that occurs when culturing cells or microorganisms. The present invention relates to a method for preventing the lysis of a host by a virus by adding an antiserum specific to the virus, and for culturing the host virus without inhibition.

細胞又は微生物の培養に際して発生するウィルス汚染の
異常現象は、アセトン・ブタノール産業。
The abnormal phenomenon of virus contamination that occurs when culturing cells or microorganisms is caused by the acetone/butanol industry.

アミラーゼ産業、L−グルタミン酸産業、インターフェ
ロンの育生、モノクローナルアンティボディの産生など
の各種の細胞又は微生物利用分野において報告されてお
り、−日一、ウィルス汚染が発生すると溶菌などの異常
現象が起こり、目的生産物が得られないばかりでなく、
広く実験室や工場内忙つィル誠が撒き散らされることか
ら、再び順調に生産、培養が行えるように環境を整備す
るのに甚大な時間と労力を要するので、工業生産上ゆゆ
しき問題となっている。
It has been reported in various cell or microbial application fields such as amylase industry, L-glutamic acid industry, interferon growth, and monoclonal antibody production. Not only can you not get any products,
This poses a serious problem in industrial production, as it requires a tremendous amount of time and effort to prepare the environment so that production and cultivation can resume smoothly, as it is widely dispersed in laboratories and factories. ing.

その対策としては、大別して抗生物質等の、細胞や微生
物の生育阻害剤を添加して混入ウィルスの作用を阻止す
る培讐方法、ウィルス耐性株を増得し、それを生産に用
いる培養方法、ウィルスと宿主との吸着を阻害するため
にキレート剤、界面活性剤、2価の金属イオンなどを添
加する培養方法などがある。これらの培養方法に関する
総説として1発酵と微生物n巻(植村、相田編集、朝倉
書店、 1970年)1〜90頁をあげることができる
Countermeasures can be broadly divided into culture methods, which add antibiotics or other growth inhibitors to cells and microorganisms to block the effects of the contaminating virus, culture methods, which increase virus-resistant strains and use them for production. There are culture methods in which chelating agents, surfactants, divalent metal ions, etc. are added to inhibit adsorption between viruses and hosts. A review of these culture methods can be found in Volume 1: Fermentation and Microorganisms, Volume N (edited by Uemura and Aida, Asakura Shoten, 1970), pages 1 to 90.

これらの培養方法のうち、抗生物質等の生育阻害剤、キ
レート剤、界面活性剤などを用いる方法は、抗生物質な
どの薬剤が高価であること、宿主に阻害を与えずウィル
スの増殖のみを抑えるだめの濃度設定が困難であること
、培養液中に残留する抗生物質などの薬剤が培養液から
の生産物の回収に支障をきたすことなどの理由により一
般には用いられていない。特に連続培養法においては。
Among these culture methods, methods that use growth inhibitors such as antibiotics, chelating agents, surfactants, etc. have the disadvantage that drugs such as antibiotics are expensive, and that they only suppress the proliferation of the virus without inhibiting the host. It is not generally used because it is difficult to set the concentration of the culture solution, and drugs such as antibiotics that remain in the culture solution interfere with the recovery of products from the culture solution. Especially in continuous culture methods.

供給する培地に常に一定濃度以上の抗生物質などの薬剤
を添加することが必要なため、経済的に著しく不利であ
る。
Since it is necessary to always add a certain concentration or more of a drug such as an antibiotic to the supplied medium, it is economically disadvantageous.

iiた。ウィルス耐性株を取得する方法は、その耐性株
取得に甚大な労力を必要とすること、耐性株を取得した
としても耐性株に対する新たなウィルスが比較的短時間
のうちに発生し、再びウィルス汚染がひき起こされるこ
となどから、ウィルス汚染の決定的な防上対策とはなり
得ない。事実。
ii. The method of obtaining virus-resistant strains requires a tremendous amount of effort to obtain the resistant strains, and even if a resistant strain is obtained, a new virus against the resistant strain will appear in a relatively short period of time, resulting in virus contamination again. It cannot be used as a definitive preventive measure against virus contamination, as it may cause fact.

発酵と工業、35巻、3号、198〜204頁(松井ら
)、1977年によれば、ウィルス耐性株を取得しても
半年〜2年以内忙ウィルス汚染が再発したことが記載さ
れている。さらにウィルス防除対策の特殊な例として、
チーズ製造に際し、ウィルスを牛に注射し、抗体を作ら
せた牛乳を用いる方法が、ジャーナル・ディリイ・リサ
ーチ(J、 DairyResearch ) 31巻
、95頁、”1964年に記載されている。この方法の
欠点は、抗体を含んだ牛乳を0.3〜1.0チと多量に
原料乳に加えないと効果がないこと、抗体を含んだ牛乳
を製造するに際し、乳牛の体が大きいことから投与する
ウィルス量が莫大量必要で、その調整が困難であること
、2次的アミロイド−シスによる抗体力価の低下やアナ
フィラキシ−によって貴重な乳牛が死亡する懸念がある
ので実用性に乏しく、そのうえ、他の細胞又は微生物の
培養原料として牛乳を用いるものは少ないので普遍的に
用いることができる方法ではない。
According to Fermentation and Industry, Vol. 35, No. 3, pp. 198-204 (Matsui et al.), 1977, it is stated that even after acquiring a virus-resistant strain, virus contamination recurred within six months to two years. . Furthermore, as a special example of virus prevention measures,
A method of injecting a virus into cows to produce antibodies and using milk for cheese production is described in the journal Dairy Research, Vol. 31, p. 95, 1964. The disadvantages are that it is not effective unless a large amount of milk containing antibodies (0.3 to 1.0 g) is added to the raw milk, and when producing milk containing antibodies, it must be administered to dairy cows because of their large bodies. It is impractical because it requires a huge amount of virus and it is difficult to adjust it, and there is a concern that valuable dairy cows may die due to a decrease in antibody titer due to secondary amyloidosis or anaphylaxis. This is not a method that can be universally used because there are few methods that use milk as a raw material for culturing cells or microorganisms.

このようにウィルス汚染を防ぐ決定的な方法がないため
、細胞又は微生物の培養の際には、ウィルスを培養装置
中に混入させないことを目的として厳密な無菌状態の確
保、培地の充分な殺菌1通気に用いる空気の殺菌、培養
室の保清に留意して生産を行っているのが現状で、経済
的な負担が大きく、また、予防的な手段でしかないこと
がら決定的なウィルス汚染防除対策が切実に望まれてい
る。
As there is no definitive method to prevent virus contamination, when culturing cells or microorganisms, it is necessary to maintain strict sterile conditions and thoroughly sterilize the culture medium in order to prevent viruses from entering the culture equipment. Currently, production is carried out with careful attention to sterilizing the air used for ventilation and keeping the culture room clean, which imposes a heavy economic burden, and since it is only a preventive measure, it is essential to prevent virus contamination. Countermeasures are desperately needed.

本発明者らは、このような実状に鑑み、抗原抗体反応を
用いてウィルスを分類する研究を行っていた際に、一般
的な方法で作成したウィルスに対する抗血清が驚くべき
ことに低濃度でも選択的にウィルスと良く結合し、その
結合が不可逆的であることからウィルスが宿主吸着性を
失うことを知り、この抗血清を培地中に共存させること
Kより。
In view of this situation, when the present inventors were conducting research to classify viruses using antigen-antibody reactions, they found that antiserum against viruses prepared using a general method surprisingly showed a high level of resistance even at low concentrations. It is known that this antiserum selectively binds well to the virus and that the binding is irreversible, which causes the virus to lose adsorption to the host, so this antiserum is allowed to coexist in the medium.

ウィルス汚染を防止できることを見い出し0本発明を完
成した。
The present invention was completed based on the discovery that virus contamination can be prevented.

すなわち9本発明は、細胞又は微生物を培養するに際し
、培地中にウィルスを中和する抗体を含んだ血清(以下
抗血清という。)添加することを特徴とする細胞又は微
生物の培養方法である。
That is, the present invention is a method for culturing cells or microorganisms, which is characterized in that, when culturing cells or microorganisms, serum containing antibodies that neutralize viruses (hereinafter referred to as antiserum) is added to the medium.

本発明に適用できる細胞としては、補乳動物由来の細胞
や細胞融合法で作られた各種ハイブリドーマがあげられ
る。また、微生物としては0例えば放線菌や細菌をあげ
ることができる。
Cells that can be applied to the present invention include cells derived from mammalian animals and various hybridomas produced by cell fusion methods. Furthermore, examples of microorganisms include actinomycetes and bacteria.

本発明に用いる抗血清を調製するには9例えば免疫学実
験入門(松橋、成内、白井著、学会出版センター、 1
981年)、細イファージ遺伝実験法(蛋白質核酸酵素
別冊、92〜101頁、共立出版。
To prepare the antiserum used in the present invention, see 9, for example, Introduction to Immunology Experiments (written by Matsuhashi, Naruchi, and Shirai, Gakkai Publishing Center, 1).
981), Thin Phage Genetic Experiment Method (Protein Nucleic Acid Enzyme Special Issue, pp. 92-101, Kyoritsu Shuppan).

1972年)、免疫化学的同定法(98〜100頁。(1972), Immunochemical Identification Methods (pp. 98-100).

東京化学同人、 1973年)に記載されている一般的
な方法に従えばよく、用いる動物としては、入手のし易
さ、血液の量が多いことから、ウサギが璃しているが1
モルモット、ラット、犬、ヒツジ等でもよい。
The general method described in Tokyo Kagaku Dojin (Tokyo Kagaku Dojin, 1973) can be followed, and rabbits are preferred because they are easily available and have a large amount of blood.
It may also be a guinea pig, rat, dog, sheep, etc.

この抗血清作製の具体的方法の一例を下記に記載する。An example of a specific method for producing this antiserum is described below.

(1)ウィルス液の作製 バクテリオファージの実験(富沢著、岩波書店1970
年)記載の方法に従い、ウィルス液を作成し、超遠心分
離機(日立製作所、70P−72)によってウィルスを
回収する。これを適当量の2mMリン酸緩衝液(PH7
,0、1mM Mg  を含む)K溶解1..1012
7’ラークフオーメーシヲンユニツト(以後PFUと略
する)/−となるように調製する。
(1) Preparation of virus solution Bacteriophage experiment (author Tomizawa, Iwanami Shoten 1970)
A virus solution is prepared according to the method described in 2010, and the virus is collected using an ultracentrifuge (Hitachi, Ltd., 70P-72). Add this to an appropriate amount of 2mM phosphate buffer (PH7).
, 0, 1mM Mg) K dissolution 1. .. 1012
It is prepared so that it becomes 7' large formation unit (hereinafter abbreviated as PFU)/-.

(2)抗血清の作製 体電約2に4のウサギの耳静脈に上記+1)のウィルス
液を3日ごとに17!ずつ4週間注射する。最後の注射
が終ってから1日間水のみを与えて飼育し。
(2) Preparation of antiserum Inject the above +1) virus solution into the ear vein of a rabbit with a body voltage of about 2 to 4 days every 3 days. Inject each for 4 weeks. After the last injection, the animals were kept with only water for 1 day.

全面を1001IIlビーカーに採血する。室温で30
分間放置し血液を凝固させ、生成した血餅をガラス棒で
管壁からはがした後、氷室に一晩入れ血清を浸出させる
。血清が分離したら、血餅ごと3000Gで5分間遠沈
し、上清の血清をとり出す。こうして通常2Kfのウサ
ギより50−の抗血清を得ることができる。抗血清は、
このまま用いることができるが、さらに精製して用いて
もよい。
Collect blood from the entire surface into a 1001II beaker. 30 at room temperature
Leave the tube for a minute to allow the blood to coagulate, remove the formed clot from the tube wall with a glass rod, and then place it in an ice chamber overnight to allow the serum to leached out. Once the serum is separated, the blood clot is centrifuged at 3000G for 5 minutes, and the supernatant serum is taken out. In this way, a 50-kf antiserum can usually be obtained from a 2kf rabbit. The antiserum is
Although it can be used as it is, it may be further purified and used.

(3)抗体力価の測定法 抗血清を適宜2mMリン酸緩衝液(Pi(7,0、1m
M Mg2+を含む)で希釈し、この希釈液0.25−
と。
(3) Measuring method of antibody titer Antiserum was appropriately added to 2mM phosphate buffer (Pi(7,0, 1m
(containing M Mg2+), and this diluted solution 0.25-
and.

11)で作製したウィルス液を適宜同組成の緩衝液で希
釈したもの0.254とを個別[37℃に保つ。5分後
1両者を混和し、経時的に残存ウィルス数を寒天下板を
用いたプラーク計数法にて測定する。次式に従い一次反
応定数(K)を求める。
The virus solution prepared in step 11) was appropriately diluted with a buffer solution of the same composition and diluted to 0.254 ml separately [kept at 37°C]. After 5 minutes, the two are mixed and the number of remaining viruses is measured over time by a plaque counting method using an agar plate. The first-order reaction constant (K) is determined according to the following formula.

抗血清の反応液中での希釈倍率をDとすると。Let D be the dilution factor of the antiserum in the reaction solution.

KD = Kはその抗血清の力価を表わす。ただし。KD = K represents the titer of the antiserum. however.

pFit分後の残留ファージ数(PFU/rd )であ
り。
The number of phages remaining after pFit minutes (PFU/rd).

Po1d最初のファージ数(pFU/y )である。Po1d is the initial phage number (pFU/y).

今、培養開始時、30分で細胞数が2倍になる細胞又は
微生物を培養する培地中に10 PFU/dのウィルス
が存在するとした場合、ウィルス汚染を防ぐために、こ
の培地1 ml中に加える最少抗血清量としては30分
以内にウィルスの生存率(P/Po )を10以下とす
、、る量である。すなわち10分でl0PFU/dのウ
ィルスの生存率を10にしよう2.3 と思えば、 K=−logIOより、に=0.69゜0 従って、R(力価) = 276の抗血清2,5μtを
培地1−中に添加すればよい。
Now, at the start of culture, if 10 PFU/d of virus is present in a medium for culturing cells or microorganisms whose number doubles in 30 minutes, add 10 PFU/d of virus to 1 ml of this medium to prevent virus contamination. The minimum amount of antiserum is the amount that will reduce the virus survival rate (P/Po) to 10 or less within 30 minutes. In other words, let's make the survival rate of a virus of 10 PFU/d in 10 minutes 102.3. From K = -logIO, 2 = 0.69°0 Therefore, R (titer) = 276 antiserum 2, 5 μt may be added to medium 1-.

また、抗血清の添加量としては、培養装置に吹込む空気
量をめやすに行うことが実際的である。
Furthermore, it is practical to adjust the amount of antiserum to be added based on the amount of air blown into the culture apparatus.

すなわち、ウィルス汚染の原因となるウィルスは。In other words, the virus that causes virus contamination.

通常1通気に用いられる空気からもたらされることがほ
とんどなので、空気中に存在するウィルス数をプラーク
計数法で測定し、空気中に含まれるウィルスが培養装置
中に全て留まるとして、空気体積当妙のウィルス数と空
気量とから、培養装置中に蓄積されるウィルス数を求め
、それらのウィルスと結合しうる等量の抗血清を培地中
に加えておくことが好ましい。通常、ウィルス汚染の起
こっていない場合の空気中ウィルス数は、 10 PF
′U/を以下であるが、ウィルス汚染が発生した場合は
、 10 PFU//、になることがある。
Since most of the virus comes from the air that is normally used for ventilation, the number of viruses present in the air is measured using the plaque counting method, and assuming that all the viruses in the air remain in the culture device, the air volume is equivalent to the number of viruses present in the air. It is preferable to determine the number of viruses accumulated in the culture device from the number of viruses and the amount of air, and add an equal amount of antiserum capable of binding to those viruses to the medium. Normally, the number of viruses in the air when there is no virus contamination is 10 PF
'U/ is below, but if virus contamination occurs, it may be 10 PFU//.

本発明に用いられる細胞又は微生物の培地としては9例
えば、動物組織培養技術(G、 D、ウオズレイ、ジョ
ンW、メイ著、山田訳、講談社1977年)や、マニュ
アル・オブ・マイクロ!(イオロジカル・メソツズ(M
anual of MicrobiologicalM
ethod 、ノサイティ・オプ・アメリカン・バイオ
ロジスツ編、マグロウヒル・ブック・カンパニー、19
57年)に記載の一般的な培地をあげることができる。
Examples of the culture medium for cells or microorganisms used in the present invention include Animal Tissue Culture Techniques (G., D., Wolley, John W., May, translated by Yamada, Kodansha 1977) and Manual of Micro! (Iological Methods (M)
annual of MicrobiologicalM
ethod, edited by Nocturne Op American Biologists, McGraw-Hill Book Company, 19
Examples include the general culture medium described in 1957).

本発明において、ウィルス抗血清を、細胞又は微生物培
地に添加する時期としては1例えば、培養のどの時点で
もよいが、P%養開開始時添加するのが好オしい。連続
培養の際には供給培地に渣)ら゛かじめ抗血清を一定量
加えておいてもよいが、抗体は、抗生物質等の薬剤と違
い低濃度でも選択的にウィルスに吸着し、解離しないの
で、一定時間ごとに断続的に少量加える方法を採用する
ことができ経済的である。例えば、バチルス・ステアロ
サーモフィラス(Bacillus Stearoth
ermophilus)UK78B株(微工研菌寄第5
141号FERM −P A3141 )を用いて連続
培養するに際し、上記抗血清を適宜添加1−て行ったと
ころ、連続培養240時間を経過してもウィルス汚染は
発生しなかりだが、抗血清を添加しないものでは、連続
培養開始後7時間でウィルス汚染が発生した。
In the present invention, the virus antiserum may be added to the cell or microbial culture medium at any time during culture, but it is preferably added at the start of P% cultivation. During continuous culture, a certain amount of antiserum may be added in advance to the supply medium, but unlike drugs such as antibiotics, antibodies selectively adsorb to viruses even at low concentrations and dissociate. Therefore, it is possible to adopt a method of adding small amounts intermittently at regular intervals, which is economical. For example, Bacillus stearothermophilus
ermophilus) UK78B strain (Feikoken Bacteria Collection No. 5
When carrying out continuous culture using No. 141 FERM-P A3141), the above antiserum was added as appropriate. No virus contamination occurred even after 240 hours of continuous culture. In those without, virus contamination occurred 7 hours after the start of continuous culture.

本発明によれば、ウィルス汚染を防止して細胞又は像生
物の培養を阻害なく順調に行うことができる。この際に
要する抗血清は培養液5760 tに対し、 160m
であり、経済性が高く、工業的にも充分適用できる。
According to the present invention, virus contamination can be prevented and cells or image organisms can be cultured smoothly without any hindrance. The antiserum required at this time is 160 m for 5760 t of culture solution.
It is highly economical and can be applied industrially.

次に実施例により本発明を具体的に説明する。Next, the present invention will be specifically explained with reference to Examples.

実施例1 100ml三角フラスコに培地〔グルコース1.75g
Example 1 Medium [glucose 1.75g] in a 100ml Erlenmeyer flask
.

(NH4)28042 g 、 KH2PO41g 、
 Na2HPO442H2019* MgSO4・7H
200,31、酵母エキス(オリエンタル酵母社製) 
1.5.9を水道水1tに溶解しPH7,0に1規定N
aOHで調整する〕を20d仕込み。
(NH4)28042 g, KH2PO41g,
Na2HPO442H2019* MgSO4・7H
200, 31, yeast extract (manufactured by Oriental Yeast Co., Ltd.)
Dissolve 1.5.9 in 1 t of tap water and add 1 N to pH 7.0.
Prepare 20d of [adjust with aOH].

121℃、 IKz/cnで10分間、加圧蒸気殺菌し
た。
Pressure steam sterilization was carried out at 121° C. and IKz/cn for 10 minutes.

冷却後、バチルス・ステアロサーモフィラスUK788
株の一80℃凍結保存哨体を無菌的に植菌1.た。
After cooling, Bacillus stearothermophilus UK788
Aseptically inoculate one 80°C cryopreserved body of the strain 1. Ta.

ロータリー・シェイカ−(高崎製作所)を用いて56℃
で101転振とり培養(160r、plm ) して、
菌濃度が波長660nmにおける吸光度(日立製作所。
56℃ using a rotary shaker (Takasaki Seisakusho)
101 shake culture (160r, plm) at
Absorbance of bacterial concentration at wavelength 660 nm (Hitachi, Ltd.)

101型分光光度計で測定、以後QD660と称す)に
して約02となった時点でUK788株に由来するウィ
ルス粒子(4X 10 PFU/d )を0.1−加え
When the temperature reached approximately 0.02 (measured with a Model 101 spectrophotometer, hereinafter referred to as QD660), 0.1 - of virus particles derived from the UK788 strain (4X 10 PFU/d) was added.

ウィルスと菌の比率(ウィルス/菌)か10となるよう
にし、さらに培養を続けると、培養液の□Dft60は
、約1時間30分後KO07に達して後。
When the ratio of virus and bacteria (virus/bacteria) was kept at 10 and the culture was continued, the □Dft60 of the culture solution reached KO07 after about 1 hour and 30 minutes.

ウィルス汚染による宿主菌の溶菌が起こり、急激にQ 
l) fi60が低下した。
Bacterial lysis of host bacteria occurs due to virus contamination, and Q
l) fi60 decreased.

次に上記とは別に上記と斯様にして菌を培養し。Next, separately from the above, the bacteria were cultured in the same manner as above.

培養液の0D660が0.2となった時点で、ウィルス
に対する抗血清(K=100)1−とウィルス粒子(ウ
ィルス/菌=10の出車とする)を同時に培養液K(2
)え、56℃で回転振とう培養すると、ウィルス汚染は
発生すす、培養液の0D660は低下することなく菌が
生育し、 Ql)66o = 0.85に達した。
When the 0D660 of the culture solution reaches 0.2, antiserum against the virus (K=100) 1- and virus particles (virus/bacteria = 10) are added to the culture solution K(2) at the same time.
) When cultured with rotary shaking at 56°C, virus contamination occurred, but the bacteria grew without decreasing the 0D660 of the culture solution, reaching Ql)66o = 0.85.

これより、抗血清を加えることによって、ウィルス汚染
を防ぐことができた。
From this, virus contamination could be prevented by adding antiserum.

実施例2 使用菌株;バチルス・ステアロサーモフィラスUK78
8株。
Example 2 Strain used: Bacillus stearothermophilus UK78
8 stocks.

パ)4養培地組成;グルコースを炭素源として他の組峻
を次のどとくのものを使用した。
B) 4. Composition of nutrient medium: Glucose was used as a carbon source and the following other materials were used.

グルコース1.75# 、 (NH4)2804211
 、酵母エキス(オリエンタル酵母社製) 1.51 
、 KH2PO4111、Na2)口’04”121(
201!!  、  MgSO4”7H2019以上の
ものを水道水1tに溶解した。
Glucose 1.75#, (NH4)2804211
, yeast extract (manufactured by Oriental Yeast Co., Ltd.) 1.51
, KH2PO4111, Na2) 口'04''121(
201! ! , MgSO4"7H2019 or higher was dissolved in 1 ton of tap water.

前培養;上記組成の栄養培地を100d容三角フラスコ
に20m1.500d容三角フラスコに100−ずつ分
注し、綿栓後、121℃、 IKf/I−F+!、 1
9分間加圧蒸気殺菌した。冷却後、 100d容三角フ
ラスコにバチルス・ステアロサーモフィラスUK788
株の凍結乾燥菌体を約5119無菌的に接種した。ロー
タリー・シェイカ−(高崎製作所)を用いて。
Preculture: A nutrient medium with the above composition was dispensed into a 100 d Erlenmeyer flask by 100 ml each. , 1
Pressure steam sterilized for 9 minutes. After cooling, add Bacillus stearothermophilus UK788 to a 100 d Erlenmeyer flask.
Approximately 5119 freeze-dried cells of the strain were inoculated aseptically. Using a rotary shaker (Takasaki Seisakusho).

55℃で一昼夜回転振とう培養(160r、P、m )
 したところ、菌体の生育がみられ、濁度が高まり。
Rotary shaking culture overnight at 55°C (160r, P, m)
As a result, bacterial growth was observed and the turbidity increased.

660nmの吸光度(日立製作所、101型分光光度計
で測定、以後OD 660と称す)が0.8〜1.OK
達したので、これを次に50〇−容三角フラスコに約5
1接種した。同条件で数時間50〇−容三角フラスコを
回転振とう培養したところw 0D660が1.0桿奪
に達したので1回転振とう培養を中止し、これを前培嘗
物として本培養への接種に用いた。
Absorbance at 660 nm (measured with a Hitachi, Model 101 spectrophotometer, hereinafter referred to as OD 660) is 0.8 to 1. OK
Next, add about 500 liters of this to a 500-capacity Erlenmeyer flask.
1 inoculation. When a 500-capacity Erlenmeyer flask was cultured under the same conditions for several hours with rotating shaking, w0D660 reached 1.0 rods, so the shaking culture was stopped and this was used as a pre-culture to inoculate the main culture. It was used for.

本培養: 30/、谷発酵槽(丸菱理化装置MSJ −
【■型下羽根タービン式)K、−上記組成の栄養培地を
201張込み、121℃、1kq/cJで15分間、加
圧蒸気殺菌した。培養条件を57士1℃、PH6,5−
−7,0(4N NaOHで調整)9通気量20t/分
(空気)。
Main culture: 30/, Tani fermenter (Marubishi Rikaki MSJ -
[2-type lower blade turbine type] K - 201 nutrient medium of the above composition was charged and sterilized with pressurized steam at 121° C. and 1 kq/cJ for 15 minutes. Culture conditions were 57°C, 1°C, pH 6,5-
-7,0 (adjusted with 4N NaOH) 9 Air flow rate 20 t/min (air).

攪拌数50Or、p、m[設定後、前培養物を約IL接
種1〜.パッチ培養を開始した。培養に伴い発泡したの
で、消泡剤(信越化学KM”−70)を少量添加した。
Agitation number: 50 Or, p, m [After setting, inoculate the preculture at about IL 1 to 1. Patch culture was started. Since foaming occurred during culture, a small amount of antifoaming agent (Shin-Etsu Chemical KM''-70) was added.

菌体の増殖をQl)660で追跡したところ、対数増殖
が起こ9.約2.5時間でQD660が1.0に至り。
When the growth of bacterial cells was tracked using Ql)660, logarithmic growth occurred.9. QD660 reached 1.0 in about 2.5 hours.

培養液中のグルコースがほとんど消費されたので(ソモ
ジネルソン法で測定)、連続培養に移しだ。
Since most of the glucose in the culture solution was consumed (measured by the Somogyi-Nelson method), the cells were transferred to continuous culture.

前もって測定した本菌株のttrmxが1.2 (1/
hr )であったので、前記組成の殺菌済み栄養培地を
24.01/hrの速度で定量ポンプを用いて連続的に
供給L I同速度で発酵槽より培養液を抜出すことで希
釈率を1.00μmax K設定し、連続培養を実施し
た。
The ttrmx of this strain measured in advance was 1.2 (1/
hr), the sterilized nutrient medium with the above composition was continuously supplied using a metering pump at a rate of 24.01/hr, and the dilution rate was adjusted by withdrawing the culture solution from the fermenter at the same rate. Continuous culture was performed with a setting of 1.00 μmax K.

抗血清は、ウィルス濃度が油気に用いた空気中に102
P FU/lであったので、3時間ごとK 2.Odの
抗血清(K=250)を添加し7’t−8また。比較の
ため、抗血清を入れないで上記と同様に行つた。その結
果、約7時間でウィルス汚染による溶菌現象がみられた
The antiserum was tested when the virus concentration was 102% in the oily air.
P FU/l, so K 2. every 3 hours. Add antiserum of Od (K=250) to 7't-8. For comparison, the same procedure as above was carried out without adding antiserum. As a result, bacteriolysis due to virus contamination was observed in about 7 hours.

これに対し、抗血清を添加した場合は、連続培養が安定
に続き、240時間後でも溶菌し、なかった。
On the other hand, when antiserum was added, continuous culture continued stably, and no bacteriolysis occurred even after 240 hours.

抗血清を入れたことによる生育阻害等の害は全く卵、ら
れなかった。
The addition of the antiserum did not cause any harm such as growth inhibition to the eggs.

特許出願人  ユニチカ株式会社Patent applicant: Unitika Co., Ltd.

Claims (2)

【特許請求の範囲】[Claims] (1)  細胞又は微生物を培養するに際し、培地中如
ウィルスを中和する抗体を含んだ血清を添加することを
特徴とする細胞又は微生物の培養方法。
(1) A method for culturing cells or microorganisms, which comprises adding serum containing an antibody that neutralizes viruses to the medium when culturing cells or microorganisms.
(2)通気に用いられる空気に含まれるウィルスを中和
するに足る力価を持つ抗体を含んだ血清を添加する特許
請求の範囲第1項記載の培養方法。
(2) The culture method according to claim 1, wherein serum containing antibodies having a titer sufficient to neutralize viruses contained in the air used for aeration is added.
JP57084623A 1982-05-18 1982-05-18 Cultivation of cell of microorganism Pending JPS58201981A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57084623A JPS58201981A (en) 1982-05-18 1982-05-18 Cultivation of cell of microorganism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57084623A JPS58201981A (en) 1982-05-18 1982-05-18 Cultivation of cell of microorganism

Publications (1)

Publication Number Publication Date
JPS58201981A true JPS58201981A (en) 1983-11-25

Family

ID=13835800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57084623A Pending JPS58201981A (en) 1982-05-18 1982-05-18 Cultivation of cell of microorganism

Country Status (1)

Country Link
JP (1) JPS58201981A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513187A (en) * 1978-04-21 1980-01-30 Standard Oil Co Preparation of mutiple component oxide complex catalyst
JPS57141293A (en) * 1981-02-27 1982-09-01 Yakult Honsha Co Ltd Preparation of lactobacillus casei

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513187A (en) * 1978-04-21 1980-01-30 Standard Oil Co Preparation of mutiple component oxide complex catalyst
JPS57141293A (en) * 1981-02-27 1982-09-01 Yakult Honsha Co Ltd Preparation of lactobacillus casei

Similar Documents

Publication Publication Date Title
Gray et al. A new technique for isolating Listerellae from the bovine brain
US8685695B2 (en) Method for producing a mixture of bacteriophages and the use thereof in the therapy of antibiotic-resistant staphylococci
Tagg et al. Bacteriocin of a group A streptococcus: partial purification and properties
Brodie et al. Fluid and solid media for isolation of Brucella abortus
US3856627A (en) Culture medium for bacteria
JPS58201981A (en) Cultivation of cell of microorganism
Hedström et al. Trioleoylglycerol lipolysis by Staphylococcus aureus strains from recurrent furunculosis, pyomyositis, impetigo and osteomyelitis
Schade et al. The preparation of a polyvalent dysentery bacteriophage in a dry and stable form: I. Preliminary investigations and general procedures
CN112899341A (en) Selective enrichment medium for yersinia enterocolitica and preparation method thereof
GB2168705A (en) Bacteriolytic enzyme and process for preparing the same
Abrehem et al. Production of a bacteriocin, ulceracin 378, by Corynebacterium ulcerans
WATT et al. Rabbit haemorrhagic disease in Saudi Arabia
US2601350A (en) Hydrolysis of beta lactam linkage by penicillinase
RU2193063C2 (en) Bacteriolytic complex, method of its preparing and strain for method realization
EP0243015B1 (en) Selective media for growth of neisseria
RU2158302C2 (en) Nutrient medium for bifidobacterium and lactobacterium culturing
RU2100029C1 (en) Medium for culturing bacterium-symbiont bacillus pulvifaciens or bacillus subtilis - a producer of probiotic
Paquette et al. Avirulent Clostridium perfringens strains obtained by euflavine treatment
Biggart Patentability in the United States of Microorganisms, Processes Utilizing Microoragnisms, Products Produced by Microorganisms and Microorganism Mutational and Genetic Modification Techniques
Porter et al. Safety evaluation of Protaminobacter rubrum: intravenous pathogenicity and toxigenicity study in rabbits and mice
RU2236458C1 (en) Strain of legionellosis bacteriophage niim active with respect to legionella pneumophila, legionella micdadei, legionella dumoffii and legionella bozemanii
THUNPITHAYAKUL Bacteriophage-associated lysin produced by Streptococcus lactis and Streptococcus cremoris.
RU2202608C2 (en) Method of leptospira culturing
Neill et al. Isolation of Neisseria ovis from an aborted bovine foetus
El-Magawry et al. AETIOLOGICAL STUDY ON RESPIRATORY AFFECTION IN CAMELS AND ITS RELATION TO HAEMATOLOGICAL AND BIOCHEMICAL CHANGES